Immune correlates of protection during gamma-herpesvirus vaccination
Immune correlates of protection during gamma-herpesvirus vaccination
批准号:
7463211
负责人:
EMILIO FLANO
金额:
$21.6万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-02-15 至 2010-01-31
关键词:
AcuteAfricanAnimal ModelAntibodiesAntigensB-LymphocytesBiologicalBiologyCD4 Positive T LymphocytesCD8B1 geneCell LineCellsCharacteristicsCytomegalovirusDataDendritic CellsDevelopmentDiseaseEpitopesEpstein-Barr Virus InfectionsGoalsHIVHIV-1HealthHealth PrioritiesHepatitis C virusHerpesviridaeHigh PrevalenceHumanHuman Herpesvirus 4Human Herpesvirus 8ImmuneImmune responseImmune systemImmunityImmunizationImmunotherapyInfectionInfection preventionKaposi SarcomaLifeMediatingMemoryMurine herpesvirus 68MusNumbersPopulationProductionPublic HealthPublishingRangeRoleSatellite VirusesSeroprevalencesSimplexvirusT memory cellT-LymphocyteTestingVaccinatedVaccinationVaccine DesignVaccinesViralViral load measurementVirusVirus DiseasesVirus Latencycytokinecytotoxicitydisorder preventionin vivoin vivo Modelinnovationlatent infectionmucosal sitenovelpathogenpreventresearch studyresponsetumorvaccination strategyvaccine evaluation
中文摘要
描述(由申请人提供):持续性病毒感染是全球主要的健康问题。人类免疫缺陷病毒(HIV-1)、爱泼斯坦-巴尔病毒(EBV)、卡波西肉瘤病毒(KSHV)、巨细胞病毒(CMV)和丙型肝炎病毒(HCV)导致免疫系统无法清除感染。其中,3-疱疹病毒是非常成功的病原体。eb病毒感染95%的人口。KSHV在非洲流行地区的血清患病率超过60%。由于3-疱疹病毒与许多疾病有关,研制3-疱疹病毒疫苗是卫生工作的重点。然而,针对一般持续性病毒,特别是3-疱疹病毒的疫苗接种已被证明是一项挑战。小鼠γ -疱疹病毒68 (MHV-68)感染为表征自然宿主的免疫反应提供了宝贵的动物模型,可用于开发针对3-疱疹病毒的疫苗。在目前的建议中,我们将确定由一种新的疫苗接种策略诱导的保护的免疫相关因素,这种策略可以改善小鼠在MHV-68攻击后的急性感染和预防潜伏期。我们的初步数据显示,接种DCS11疫苗后,在急性感染期间病毒载量减少了5万倍,并且无法检测到病毒潜伏期。在目标1中,我们将确定DCS11疫苗接种免疫反应的功能特征。在目标2中,我们将通过分析接种dcs11的小鼠对病毒攻击的召回反应来确定疫苗保护的机制。这些研究产生的信息将对我们理解针对3-疱疹病毒的疫苗如何产生保护作用至关重要,它可能有助于开发针对持续病毒感染的免疫疗法。
英文摘要
DESCRIPTION (provided by applicant): Persistent viral infections are a major health problem worldwide. The inability of the immune system to clear infection characterizes life-long persistence by human immunodeficiency virus (HIV-1), Epstein- Barr virus (EBV), Kaposi's sarcoma virus (KSHV), cytomegalovirus (CMV) and hepatitis C virus (HCV). Among them, the 3-herpesviruses are very successful pathogens. EBV infects 95% of the human population. KSHV seroprevalence exceeds 60% in endemic African regions. Due to their association with a large number of diseases a vaccine for 3-herpesviruses is a health priority. Nevertheless, vaccination against persistent viruses in general, and 3-herpesviruses in particular, has proven a challenge. Infection of mice with murine gamma-herpesvirus 68 (MHV-68) provides an invaluable animal model to characterize immune responses in a natural host that may be used to develop vaccines against 3-herpesvirues. In the current proposal, we will identify the immune correlates of protection induced by a novel vaccination strategy that ameliorate acute infection and prevent latency in mice after MHV-68 challenge. Our preliminary data show that after DCS11 vaccination there is a reduction in virus load by a 50,000-fold during acute infection and that viral latency cannot be detected. In Aim 1, we will determine the functional characteristics of the immune response to DCS11 vaccination. In Aim 2, we will identify the mechanism(s) of vaccine protection by analyzing the recall response to a virus challenge in DCS11-vaccinated mice. The information generated by these studies will be critical for our understanding of how vaccines against 3-herpesviruses can elicit protection, and it will likely aid in the development of immune therapies against persistent viral infections.
PUBLIC HEALTH RELEVANCE: Persistent viral infections are a major health problem worldwide. The goal of the present application is to determine the immune correlates of protection induced by our novel vaccination strategy that ameliorate acute infection and prevent latency in mice after murine 3-herpesvirus challenge. The information generated by these studies will be critical for our understanding of how vaccines against 3-herpesviruses can elicit protection, and it will likely aid in the development of immune therapies against persistent viral infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of T lymphocyte immunology to influenza virus
-
批准号:7929503
-
项目类别:
-
资助金额:$42.46万
-
财政年份:2009
-
负责人:EMILIO FLANO
-
依托单位:
Regulation of T lymphocyte immunology to influenza virus
-
批准号:7679754
-
项目类别:
-
资助金额:$41.43万
-
财政年份:2009
-
负责人:EMILIO FLANO
-
依托单位:
Immune correlates of protection during gamma-herpesvirus vaccination
-
批准号:7569940
-
项目类别:
-
资助金额:$18.0万
-
财政年份:2008
-
负责人:EMILIO FLANO
-
依托单位:
Gamma-herpesvirus infection of dendritic cells
-
批准号:6865315
-
项目类别:
-
资助金额:$28.4万
-
财政年份:2005
-
负责人:EMILIO FLANO
-
依托单位:
Gamma-herpesvirus infection of dendritic cells
-
批准号:7188965
-
项目类别:
-
资助金额:$26.93万
-
财政年份:2005
-
负责人:EMILIO FLANO
-
依托单位:
Dendritic Cell Function in Lung Viral Infection
-
批准号:8301828
-
项目类别:
-
资助金额:$32.58万
-
财政年份:2005
-
负责人:EMILIO FLANO
-
依托单位:
Gamma-herpesvirus infection of dendritic cells
-
批准号:7024520
-
项目类别:
-
资助金额:$27.73万
-
财政年份:2005
-
负责人:EMILIO FLANO
-
依托单位:
Gamma-herpesvirus infection of dendritic cells
-
批准号:7371906
-
项目类别:
-
资助金额:$26.42万
-
财政年份:2005
-
负责人:EMILIO FLANO
-
依托单位:
Gamma-herpesvirus infection of dendritic cells
-
批准号:7576710
-
项目类别:
-
资助金额:$26.42万
-
财政年份:2005
-
负责人:EMILIO FLANO
-
依托单位:
海外基金